Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	9.35	6.75	3.55
Depreciation & Amortization Expenses	0.01	0	0
Research & Development	4.1	4.21	4.08
Total Operating Expenses	13.46	10.96	7.63
Operating Income	-13.46	-10.96	-7.63
Interest Income	0.22	0.31	0.25
Interest Expense	-	-	-0.02
Other Non-Operating Income (Expense)	-	-	-0.96
Total Non-Operating Income (Expense)	0.22	0.31	-0.72
Pretax Income	-13.24	-10.65	-8.36
Net Income	-13.24	-10.65	-8.36
Net Income to Common	-13.24	-10.65	-8.36
Shares Outstanding (Basic)	2	1	1
Shares Outstanding (Diluted)	2	1	1
Shares Change (YoY)	63.48%	35.59%	-
EPS (Basic)	-6.64	-8.73	-9.29
EPS (Diluted)	-6.64	-8.73	-9.29
Shares Outstanding	2.34	1.78	0.87
Free Cash Flow	-12.61	-7.36	-3.53
Free Cash Flow Per Share	-6.32	-6.04	-3.93
EBITDA	-13.45	-10.96	-7.63
EBIT	-13.46	-10.96	-7.63

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q